PTC Therapeutics (PTCT) said late Wednesday the US Food and Drug Administration has accelerated approval of Kebilidi, the company's gene therapy for the treatment of aromatic L-amino acid decarboxylase deficiency.
The therapy, also called eladocagene exuparvovec-tneq, is for the treatment of children and adults across the full spectrum of the rare, life-shortening genetic deficiency, the company said.
Treatment centers have already been identified and surgeons already trained to administer the treatment, which is injected directly into the brain, the company said.
The drug received accelerated approval based on results of an ongoing clinical trial, the company said.
Shares of the company were up 5% in Wednesday's after-hours activity.
Price: 46.23, Change: +2.20, Percent Change: +5.00
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.